HKG: 6887

Autobio Diagnostics and Haier Biomedical Sign Strategic Cooperation Agreement – AI‑Driven Alliance to Build Holistic Smart Laboratory Solutions Across IVD, Automation, and Medical Informatization
CompanyDeals

Autobio Diagnostics and Haier Biomedical Sign Strategic Cooperation Agreement – AI‑Driven Alliance to Build Holistic Smart Laboratory Solutions Across IVD, Automation, and Medical Informatization

Autobio Diagnostics Co., Ltd. (SHA: 603658) and Haier Biomedical (SHA: 688139) signed a strategic cooperation agreement, joining forces across in vitro diagnostics (IVD), laboratory automation, and medical informatization to drive…

TenNor Therapeutics Reports Multiple R&D Milestones for Rifasutenizol and Rifaquinone – NDA Supplementary Package Complete as First‑in‑Class Triple‑Target Agent Advances Against Device‑Associated Infections

TenNor Therapeutics Reports Multiple R&D Milestones for Rifasutenizol and Rifaquinone – NDA Supplementary Package Complete as First‑in‑Class Triple‑Target Agent Advances Against Device‑Associated Infections

CureGene Pharmaceutical and Walvax Biotechnology Sign Strategic MOU – Full‑Chain Alliance to Accelerate Innovative Nucleic Acid Drugs from AI‑Enabled mRNA R&D to Large‑Scale Manufacturing

CureGene Pharmaceutical and Walvax Biotechnology Sign Strategic MOU – Full‑Chain Alliance to Accelerate Innovative Nucleic Acid Drugs from AI‑Enabled mRNA R&D to Large‑Scale Manufacturing

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Sunshine Lake Pharma Wins NMPA Approval for Dual Insulin Analogue Injection – Fixed‑Ratio Degludec/Aspart Targets Fasting and Postprandial Glucose in One Formulation
CompanyDrug

Sunshine Lake Pharma Wins NMPA Approval for Dual Insulin Analogue Injection – Fixed‑Ratio Degludec/Aspart Targets Fasting and Postprandial Glucose in One Formulation

CompanyDrug

Sunshine Lake Pharma Advances Novel LY6G6D/4-1BB Bispecific Antibody HEC-921 Toward Phase I Clinical Trials in China

CompanyDrug

Sunshine Lake Pharma Secures NMPA Approval for In-House Developed Premixed Insulin 30R Prefilled Pen

Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture
CompanyDeals

Sunshine Lake Pharma and Xtalpi Form AI Drug Discovery Joint Venture

Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins
CompanyDigital

Sunshine Lake Pharma Launches AI-Powered PROTAC Platform to Target Undruggable Proteins

Sunshine Lake Pharma Lists on HKEX via Introduction Method
CompanyDeals

Sunshine Lake Pharma Lists on HKEX via Introduction Method